-
بيت
-
منتج
-
الكيمياء المناعية
-
أداة
-
جزيئي
-
الأنسجة
-
علم الخلايا
-
علم الأمراض الرقمية
-
-
Solution
-
يدعم
-
عن
-
اتصال
فئة المنتج
ETV6/NTRK3 Fusion Gene t (12;15) Probe Reagent (Fluorescence in Situ Hybridization)
Clinic Signification：
1. Vitrakvi is the first FDA-approved oral TRK inhibitor to be marketed and also the first "broad-spectrum" anticancer drug that has nothing to do with tumor type. Targeted therapy for patients with NTRK gene (NTRK1/2/3) fusion , including: lung cancer, thyroid cancer, melanoma, gastrointestinal cancer, colon cancer, soft tissue sarcoma, salivary glands, infantile fibrosarcoma, appendix cancer, breast cancer, cholangiocarcinoma, pancreatic cancer etc.
محادثة
رسالة
يقتبس
Contrast
ETV6/NTRK3
NTRK3/ETV6 Fusion
ETV6 Breakpart
مزيد من المعلومات
Probe Description: ETV6/NTRK3
Cat.No.: CF1078
Specification: 5 tests/box;10 tests/box, 20 tests/box
المنتج ذي الصلة
